Retatrutide vs Tirzepatide

The shape of the comparison

Both compounds are once-weekly subcutaneous peptides that reduce body weight in obesity trials. They share the GLP-1 receptor mechanism that drives appetite suppression and delayed gastric emptying. They diverge on the additional receptors each compound activates — and that divergence drives the gap in headline weight-loss numbers.

Tirzepatide adds GIP receptor agonism to GLP-1. GIP appears to amplify GLP-1's effect on insulin secretion and may modulate the GI tolerability of the molecule. Retatrutide adds both GIP and glucagon receptor agonism on top of GLP-1. The glucagon component adds a metabolic-rate effect that pure GLP-1 and dual GLP-1/GIP agonists do not have — energy expenditure goes up rather than just calorie intake going down.

Receptor design at a glance

Headline weight-loss readouts

The numbers below are headline percentages from published Phase 2 and Phase 3 trial arms. They are not from head-to-head trials, so they cannot be compared the way two arms of the same trial can — but they document the rough difference in scale.

The TRIUMPH-4 figure comes from the April 2026 readout. The headline takeaway: at matched dose tier and observation window, retatrutide is producing larger percentages — driven by the glucagon component contributing to energy expenditure on top of the appetite-suppression both compounds share.

Dose ladders

Both use slow weekly titration to manage GI side effects. The mg numbers are not directly comparable across compounds because receptor potencies differ, but the ladder shape is similar.

Pharmacokinetics

Side-effect profile

Both compounds are dominated by GI events: nausea, vomiting, diarrhea, constipation. The shape is similar; the incidence is slightly different. Retatrutide trials show higher nausea incidence at the top dose tier, consistent with the glucagon component and the steeper metabolic effect. Both clear most GI events with slow titration and dose holds.

Tirzepatide has more years of post-approval data and a larger safety database; retatrutide is still in Phase 3 and its long-tail safety profile will sharpen as TRIUMPH readouts continue. Cardiovascular outcome data is not yet mature for retatrutide.

What this means for a research-context comparison

If the research question is which compound produces larger weight-loss percentages in trial populations, retatrutide is currently the larger number across published Phase 2 and Phase 3 readouts. If the research question is which compound has the deeper post-approval safety record, tirzepatide is unambiguously ahead. Tirzepatide is approved; retatrutide is not.

For purity verification of retatrutide research material specifically, see the COA library for the current batches: RET-20-C-2604-001 (20mg pen, 99.841% HPLC), RET-20-V-2604-001 (vial line, full panel), and RETP002 (30mg pen flagship).